Skip to content
Home
Shu-Yuan Yeh, Ph.D.

Shu-Yuan Yeh, Ph.D.

Contact

Office (585) 273-2750

About Me

Faculty Appointments

Professor - Department of Urology (SMD)

Credentials

Education

PhD | Univ Wisconsin-Madison. Endocrinology/Molecular Oncology. 1996

MS | National Taiwan University. Biochemical Science. 1991

BS | National Taiwan University. Medical Biotechnology/Immunology. 1988

Awards

AUA Best Poster. 2019

SBUR Best Poster award. 2012

AUA Best Poster. 2007

Outstanding publication award in Department of Pathology. 2005 - 2006

Traveling Award for Outstanding Oral Presentation. 2003

Outstanding Young Investigator Award. 2001

NIH Postdoctoral Fellowship. 1999

Travel Award for Outstanding Oral Presentation. 1997

Keystone Meeting Travel Award for Outstanding Oral Presentation. 1996

CaPCURE Research Award. 1996

CaPCURE Research Award. 1995

Research

Dr. Yeh's research projects focus mainly on studying the roles of the estrogen receptor (ER) and androgen receptor (AR) in urological diseases, including prostate cancer, bladder cancer, benign prostatic hyperplasia (BPH), and in male fertility. Dr. Yeh's lab has successfully utilized a broad range ...
Dr. Yeh's research projects focus mainly on studying the roles of the estrogen receptor (ER) and androgen receptor (AR) in urological diseases, including prostate cancer, bladder cancer, benign prostatic hyperplasia (BPH), and in male fertility. Dr. Yeh's lab has successfully utilized a broad range of research strategies, with in vitro biochemistry and molecular biology and in vivo animal models, to delineate the biological roles of the AR and ER. In the earlier stages of her career, Dr. Yeh focused on the mechanistic study of the roles of AR and AR associated proteins in androgen responsive and hormonal refractory prostate cancer. Dr. Yeh was the first scientist to clone AR associated protein in 1996, and to create and report on AR knockout (ARKO) mice using the cre-loxP strategy in 2002. The floxed AR mouse has now been successfully applied to knock out the AR gene in selective types of cells, including cells in prostate, testis, bladder, liver, brain, and others. Continuing with her success, Dr. Yeh's lab now has established genetically engineered ERalpha knockout (ERaKO) mice using this cre-loxP strategy.

Dr. Yeh has published papers to validate the usage of Cre-LoxP ERaKO mice and found the defects of prostate ductal morphogenesis and male fertility in this established ERaKO mice model. This cre-loxP ERaKO model represents a more complete ERaKO mouse model and is being used to delineate ERa roles in urological diseases in Dr. Yeh's lab. Furthermore, the lab has identified new ER binding proteins and ER target genes involved in disease progression.

Overall, Dr. Yeh's research strength is in hormone receptors, mechanisms of tumor suppressor and animal model-related studies in prostate cancer and urological disorders. To date, Dr. Yeh has published 78 peer-reviewed papers and 17 review articles on urological diseases. Currently, Dr. Yeh's research projects are supported by the NCI and the Department of Defense.

Patents

Creation of Female Mice without Androgen Receptor and Creation

Issue date: December 14, 2006

Patent #: 531,223

Country: New Zealand

Inventors: Chawnshang Chang, Shu-Yuan Yeh

Publications

Journal Articles

Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.

Xiao Y; Sun Y; Liu G1; Zhao J; Gao Y; Yeh S; Gong L; Chang C.

Cancer Letter. 2108; .

Estrogen receptor beta increases clear cell renal cell carcinoma stem cell phenotype via altering the circPHACTR4/miR-34b-5p/c-Myc signaling.

Wang Y, Yang Z, Gu J, Zhang Y, Wang X, Teng Z, Wang D, Gao L, Li W, Yeh S, Han Z

FASEB journal : official publication of the Federation of American Societies for Experimental Biology.. 2022 February 36 (2):e22163. Epub 1900 01 01.

Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ER?/Hif2-? signaling.

He M, Yang H, Shi H, Hu Y, Chang C, Liu S, Yeh S

Cancer letters.. 2022 January 1524 :15-28. Epub 08/27/2021.

R-2HG downregulates ER? to inhibit cholangiocarcinoma via the FTO/m6A-methylated ER?/miR16-5p/YAP1 signal pathway.

Gao Y, Ouyang X, Zuo L, Xiao Y, Sun Y, Chang C, Qin X, Yeh S

Molecular therapy oncolytics.. 2021 December 1723 :65-81. Epub 07/10/2021.

Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies.

Lu X, Meng J, Su L, Jiang L, Wang H, Zhu J, Huang M, Cheng W, Xu L, Ruan X, Yeh S, Liang C, Yan F

Clinical and translational medicine.. 2021 December 11 (12):e601. Epub 1900 01 01.

Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPAR?/MMP-9 signals.

Deng G, Wang R, Sun Y, Huang CP, Yeh S, You B, Feng C, Li G, Ma S, Chang C

Cell death and differentiation.. 2021 July 28 (7):2145-2159. Epub 06/14/2021.

Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR.

You B, Sun Y, Luo J, Wang K, Liu Q, Fang R, Liu B, Chou F, Wang R, Meng J, Huang CP, Yeh S, Chang C, Xu W

Oncogene.. 2021 March 40 (9):1674-1689. Epub 01/28/2021.

ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.

Tian H, Chou FJ, Tian J, Zhang Y, You B, Huang CP, Yeh S, Niu Y, Chang C

Journal of experimental & clinical cancer research : CR.. 2021 January 440 (1):3. Epub 01/04/2021.

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.

Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T,

The Lancet. Neurology.. 2021 January 20 (1):49-59. Epub 11/16/2020.

Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.

Chen D, Chou FJ, Chen Y, Tian H, Wang Y, You B, Niu Y, Huang ZP, Yeh S, Xing N, Chang C

Cancer letters.. 2020 December 28495 :100-111. Epub 08/06/2020.

The miR-92a-2-5p in exosomes from macrophages increases liver cancer cells invasion via altering the AR/PHLPP/p-AKT/?-catenin signaling.

Liu G, Ouyang X, Sun Y, Xiao Y, You B, Gao Y, Yeh S, Li Y, Chang C

Cell death and differentiation.. 2020 December 27 (12):3258-3272. Epub 06/25/2020.

Corrigendum to 'New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells'.

Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Yamashita S, Liang L, Tian J, Li L, Jiang Q, Huang CK, Niu Y, Yeh S, Chang C

Journal of molecular cell biology.. 2020 November 2512 (12):991-992. Epub 1900 01 01.

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.

Chou FJ, Lin C, Tian H, Lin W, You B, Lu J, Sahasrabudhe D, Huang CP, Yang V, Yeh S, Niu Y, Chang C

Cell death & disease.. 2020 November 211 (11):942. Epub 11/02/2020.

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells.

Lin C, Chou FJ, Lu J, Lin W, Truong M, Tian H, Sun Y, Luo J, Yang R, Niu Y, Nadal R, Antonarakis ES, Cordon-Cardo C, Sahasrabudhe D, Huang CP, Yeh S, Li G, Chang C

Aging.. 2020 September 1012 (17):17694-17712. Epub 09/10/2020.

Corrigendum to "Infiltrating neutrophils promote renal cell carcinoma (RCC) proliferation via modulating androgen receptor (AR)???c-Myc signals" [Cancer Lett. 2015 Nov 1 368(1) 71-78].

Song W, Li L, He D, Xie H, Chen J, Yeh CR, Sien-Shih Chang L, Yeh S, Chang C

Cancer letters.. 2020 August 10485 :66. Epub 05/30/2020.

Estrogen receptor ? promotes lung cancer cell invasion via increase of and cross-talk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways.

He M, Yu W, Chang C, Miyamoto H, Liu X, Jiang K, Yeh S

Molecular oncology.. 2020 August 14 (8):1779-1799. Epub 06/28/2020.

Correction to: Androgen receptor regulates expression of skeletal muscle-specific proteins and muscle cell types.

Altuwaijri S, Lee DK, Chuang KH, Ting HJ, Yang Z, Xu Q, Tsai MY, Yeh S, Hanchett LA, Chang HC, Chang C

Endocrine.. 2020 August 69 (2):474-475. Epub 1900 01 01.

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.

Wang K, Luo J, Yeh S, You B, Meng J, Chang P, Niu Y, Li G, Lu C, Zhu Y, Antonarakis ES, Luo J, Huang CP, Xu W, Chang C

Nature communications.. 2020 June 111 (1):2689. Epub 06/01/2020.

Targeting the ER?/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC.

Gu J, Zhang Y, Han Z, Gao L, Cui J, Sun Y, Niu Y, You B, Huang CP, Chang C, Wang X, Yeh S

Cell death & disease.. 2020 May 1411 (5):367. Epub 05/14/2020.

Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion.

Chen J, Sun Y, Ou Z, Yeh S, Huang CP, You B, Tsai YC, Sheu TJ, Zu X, Chang C

EMBO reports.. 2020 April 321 (4):e48467. Epub 02/13/2020.

Targeting the estrogen receptor alpha (ER?)-mediated circ-SMG1.72/miR-141-3p/Gelsolin signaling to better suppress the HCC cell invasion.

Xiao Y, Liu G, Sun Y, Gao Y, Ouyang X, Chang C, Gong L, Yeh S

Oncogene.. 2020 March 39 (12):2493-2508. Epub 01/29/2020.

Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated G?i protein/MAPK/MMP9 intracellular signaling.

Chen J, Chou F, Yeh S, Ou Z, Shyr C, Huang C, Xiang Z, Sun Y, Messing E, Zu X, Chang C

Oncogene.. 2020 January 39 (3):574-586. Epub 09/10/2019.

ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-?B survival signals.

Huang CP, Chen J, Chen CC, Liu G, Zhang Y, Messing E, Yeh S, Chang C

Journal of experimental & clinical cancer research : CR.. 2019 June 2438 (1):275. Epub 06/24/2019.

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.

Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao Y, Xu W, Niu Y, Cheng L, Maity SN, Jiang R, Chang C

Nature communications.. 2019 June 1210 (1):2571. Epub 06/12/2019.

Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals.

Zhu W, Zhao Z, Chou F, Zuo L, Liu T, Yeh S, Bushinsky D, Zeng G, Chang C

Cell death & disease.. 2019 March 2010 (4):275. Epub 03/20/2019.

Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.

Luo J, Tian J, Chou F, Lin C, Xing EZ, Zuo L, Niu Y, Yeh S, Chang C

Cancer letters.. 2019 March 1444 :35-44. Epub 09/21/2018.

Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.

Xiao Y, Sun Y, Liu G, Zhao J, Gao Y, Yeh S, Gong L, Chang C

Cancer letters.. 2019 March 1444 :175-187. Epub 11/15/2018.

Estrogen receptor ? promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer.

Yu W, Ding J, He M, Chen Y, Wang R, Han Z, Xing EZ, Zhang C, Yeh S

Oncogene.. 2019 February 38 (8):1225-1238. Epub 09/24/2018.

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.

Chang C, Yeh S, Keng P, Li G, Niu Y, Chen D, Chen Y, Chou FJ

EBioMedicine.. 2019 February 40 :504-516. Epub 01/26/2019.

The Protective Roles of Estrogen Receptor in Renal Calcium Oxalate Crystal Formation Reducing the Liver Oxalate Biosynthesis and Renal Oxidative Stress-Mediated Cell Injury.

Zhu W, Zhao Z, Chou FJ, Zuo L, Liu T, Bushinsky D, Chang C, Zeng G, Yeh S

Oxidative medicine and cellular longevity.. 2019 2019 :5305014. Epub 04/17/2019.

ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.

Niu Y, Guo C, Wen S, Tian J, Luo J, Wang K, Tian H, Yeh S, Chang C

Cancer letters.. 2018 December 28439 :47-55. Epub 09/15/2018.

Targeting newly identified ER?/TGF-?1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ER? selective antagonist in renal cell carcinoma.

Song W, He D, Chen Y, Yeh CR, Hsu I, Huang Q, Zhang X, Chang LS, Zuo L, Chen J, Doersch KM, Chang C, Yeh S

Molecular oncology.. 2018 December 12 (12):2055-2071. Epub 10/30/2018.

Estrogen receptor ? promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals.

Ou Z, Wang Y, Chen J, Tao L, Zuo L, Sahasrabudhe D, Joseph J, Wang L, Yeh S

Experimental & molecular medicine.. 2018 November 2050 (11):1-11. Epub 11/20/2018.

TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals.

Bai J, Yeh S, Qiu X, Hu L, Zeng J, Cai Y, Zuo L, Li G, Yang G, Chang C

Oncogene.. 2018 November 37 (44):5901-5912. Epub 07/04/2018.

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D

Bladder cancer.. 2018 October 34 (Suppl 1):S1-S43. Epub 10/03/2018.

Estrogen receptor ? promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network.

Ding J, Yeh CR, Sun Y, Lin C, Chou J, Ou Z, Chang C, Qi J, Yeh S

Oncogene.. 2018 September 37 (37):5037-5053. Epub 05/23/2018.

Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor ?/IL-1/c-MET signals.

Tao L, Qiu J, Slavin S, Ou Z, Liu Z, Ge J, Guancial EA, Messing EM, Chang C, Yeh S

Cancer letters.. 2018 August 28430 :215-223. Epub 04/22/2018.

ER?-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma.

Han Z, Zhang Y, Sun Y, Chen J, Chang C, Wang X, Yeh S

Cancer research.. 2018 May 1578 (10):2550-2563. Epub 02/28/2018.

Androgen receptor (AR) degradation enhancer ASC-J9 in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.

Cheng MA, Chou FJ, Wang K, Yang R, Ding J, Zhang Q, Li G, Yeh S, Xu D, Chang C

Cancer letters.. 2018 March 28417 :182-191. Epub 01/17/2018.

Estrogen receptor ? promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network.

Ding J;, Yeh CR; Sun Y; Lin C; Chou J; Ou Z; Chang C; Qi J; Yeh S.

Oncogene. 2018; .

Targeting newly identified ER?/TGF-?1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ER? selective antagonist in renal cell carcinoma.

Song W;, He D;, Chen Y; Yeh CR; Hsu I; Huang Q;, Zhang X; Chang LS; Zuo L;, Chen J; Doersch KM; Chang C; Li L; Yeh S.

Molecular oncology. 2018; .

Estrogen receptor ? promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals.

Ou Z; Wang Y; Chen J; Tao L; Zuo L3; Sahasrabudhe D; Joseph J; Wang L; Yeh S.

Exp Mol Med. 2018; .

Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.

Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C.

Cancer Letter. 2018; .

Estrogen receptors orchestrate cell growth and differentiation to facilitate liver regeneration.

Kao TL, Kuan YP, Cheng WC, Chang WC, Jeng LB, Yeh S, Ma WL

Theranostics.. 2018 8 (10):2672-2682. Epub 04/09/2018.

Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.

Chen J, Li L, Yang Z, Luo J, Yeh S, Chang C

Cancer letters.. 2017 November 1408 :155-163. Epub 08/18/2017.

Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 to Suppress Enzalutamide-resistant Prostate Cancer Progression.

Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, Antonarakis ES, Luo J, Yeh S, Chang C

European urology.. 2017 November 72 (5):835-844. Epub 05/18/2017.

Estrogen-Estrogen Receptor ? Signaling Facilitates Bilirubin Metabolism in Regenerating Liver Through Regulating Cytochrome P450 2A6 Expression.

Kao TL, Chen YL, Kuan YP, Chang WC, Ho YC, Yeh S, Jeng LB, Ma WL

Cell transplantation.. 2017 November 26 (11):1822-1829. Epub 1900 01 01.

Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).

Lin SJ, Chou FJ, Li L, Lin CY, Yeh S, Chang C

Cancer letters.. 2017 July 10398 :62-69. Epub 03/31/2017.

Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.

Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C

Cancer letters.. 2017 July 1397 :133-143. Epub 03/18/2017.

Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals.

Wang Y, Ou Z, Sun Y, Yeh S, Wang X, Long J, Chang C

Oncogene.. 2017 March 2336 (12):1644-1654. Epub 11/21/2016.

Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.

Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C.

Eur Urol. 2017; .

Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.

Wen S, Niu Y, Lee SO, Yeh S, Shang Z, Gao H, Li Y, Chou F, Chang C

Molecular carcinogenesis.. 2016 December 55 (12):2278-2290. Epub 02/19/2016.

Corrigendum to "Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11?miRNA-541?androgen receptor (AR)?MMP9 signaling" [Mol Oncol 9 (1) (2015) 44-57].

Hu S, Li L, Yeh S, Cui Y, Li X, Chang HC, Jin J, Chang C

Molecular oncology.. 2016 December 10 (10):1628-1629. Epub 11/04/2016.

Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.

Cui Y, Sun Y, Hu S, Luo J, Li L, Li X, Yeh S, Jin J, Chang C

Oncogene.. 2016 November 2435 (47):6065-6076. Epub 07/04/2016.

New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.

Lin SJ, Chou FJ, Lin CY, Chang HC, Yeh S, Chang C

Oncotarget.. 2016 October 117 (41):66769-66775. Epub 1900 01 01.

Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1?Androgen Receptor?HIF1??VEGFa Signals.

Tao L, Qiu J, Jiang M, Song W, Yeh S, Yu H, Zang L, Xia S, Chang C

Molecular cancer therapeutics.. 2016 August 15 (8):1943-1951. Epub 05/11/2016.

ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.

Wen S, Tian J, Niu Y, Li L, Yeh S, Chang C

Cancer letters.. 2016 July 1376 (2):377-86. Epub 04/01/2016.

Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.

Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S

Oncotarget.. 2016 May 107 (19):27325-35. Epub 1900 01 01.

Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.

Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Yeh S, Cai X, Chang C

Cancer letters.. 2016 April 1373 (1):45-56. Epub 01/19/2016.

Targeting Androgen Receptor (AR)?IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.

Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C

Molecular cancer therapeutics.. 2016 April 15 (4):731-742. Epub 03/03/2016.

Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ER?/CCL2/CCR2 EMT/MMP9 signals.

Rao Q, Chen Y, Yeh CR, Jie D, Li L, Chang C, Yeh S

Oncotarget.. 2016 February 167 (7):7842-55. Epub 1900 01 01.

Estrogen receptor ? in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment.

Yeh CR, Slavin S, Da J, Hsu I, Luo J, Xiao GQ, Ding J, Chou FJ, Yeh S

Molecular cancer.. 2016 January 2015 :7. Epub 01/20/2016.

Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer

Shang Z; Li Y; Hsu I; Zhang M1, Tian J; Wen S;, Han R; Messing EM; Chang C; Niu Y; Yeh S.

Oncotarget. 2016; .

Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor ?-DAB2IP signals.

Yeh CR, Ou ZY, Xiao GQ, Guancial E, Yeh S

Oncotarget.. 2015 December 296 (42):44346-59. Epub 1900 01 01.

Infiltrating neutrophils increase bladder cancer cell invasion via modulation of androgen receptor (AR)/MMP13 signals.

Lin C, Lin W, Yeh S, Li L, Chang C

Oncotarget.. 2015 December 156 (40):43081-9. Epub 1900 01 01.

Infiltrating neutrophils promote renal cell carcinoma (RCC) proliferation via modulating androgen receptor (AR)???c-Myc signals.

Song W, Li L, He D, Xie H, Chen J, Yeh CR, Chang LS, Yeh S, Chang C

Cancer letters.. 2015 November 1368 (1):71-78. Epub 07/29/2015.

Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.

Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C

Molecular cancer therapeutics.. 2015 November 14 (11):2586-94. Epub 08/11/2015.

Proteomic analysis of urethral protein expression in an estrogen receptor ?-deficient murine model of stress urinary incontinence.

Chen YH, Chen CJ, Lin YN, Wu YC, Hsieh WT, Wu BT, Ma WL, Chen WC, Tsai KS, Wu SY, Chang C, Chen HY, Yeh S

World journal of urology.. 2015 October 33 (10):1635-43. Epub 01/11/2015.

Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals.

Ou Z, Wang Y, Liu L, Li L, Yeh S, Qi L, Chang C

Oncotarget.. 2015 September 226 (28):26065-78. Epub 1900 01 01.

TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures.

Sha K, Yeh S, Chang C, Nastiuk KL, Krolewski JJ

Oncotarget.. 2015 September 226 (28):25726-40. Epub 1900 01 01.

Quantitative volumetric imaging of normal, neoplastic and hyperplastic mouse prostate using ultrasound.

Singh S, Pan C, Wood R, Yeh CR, Yeh S, Sha K, Krolewski JJ, Nastiuk KL

BMC urology.. 2015 September 2115 :97. Epub 09/21/2015.

Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2? and estrogen receptor ? signals.

Song W, Yeh CR, He D, Wang Y, Xie H, Pang ST, Chang LS, Li L, Yeh S

Oncotarget.. 2015 August 76 (22):19290-304. Epub 1900 01 01.

Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells ? androgen receptor (AR) ? miRNA32 signals.

Dang Q, Li L, Xie H, He D, Chen J, Song W, Chang LS, Chang HC, Yeh S, Chang C

Molecular oncology.. 2015 August 9 (7):1241-51. Epub 03/05/2015.

BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts.

Wen S, Niu Y, Yeh S, Chang C

International journal of oncology.. 2015 August 47 (2):719-27. Epub 06/22/2015.

Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.

Li L, Dang Q, Xie H, Yang Z, He D, Liang L, Song W, Yeh S, Chang C

Oncotarget.. 2015 June 106 (16):14179-90. Epub 1900 01 01.

Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-?1/Smad/MMP9 signals.

Xie H, Li L, Zhu G, Dang Q, Ma Z, He D, Chang L, Song W, Chang HC, Krolewski JJ, Nastiuk KL, Yeh S, Chang C

Oncotarget.. 2015 May 206 (14):12326-39. Epub 1900 01 01.

Abnormal mitochondrial function and impaired granulosa cell differentiation in androgen receptor knockout mice.

Wang RS, Chang HY, Kao SH, Kao CH, Wu YC, Yeh S, Tzeng CR, Chang C

International journal of molecular sciences.. 2015 April 3016 (5):9831-49. Epub 04/30/2015.

Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11?miRNA-541?androgen receptor (AR)?MMP9 signaling.

Hu S, Li L, Yeh S, Cui Y, Li X, Chang HC, Jin J, Chang C

Molecular oncology.. 2015 January 9 (1):44-57. Epub 07/29/2014.

Fibroblast ER? promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment.

Yeh CR, Hsu I, Song W, Chang H, Miyamoto H, Xiao GQ, Li L, Yeh S

American journal of cancer research.. 2015 5 (3):1146-57. Epub 02/15/2015.

Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients.

Wang X, Ring BZ, Seitz RS, Ross DT, Woolf K, Beck RA, Hicks DG, Yeh S

BMC clinical pathology. 2015 15 :21. Epub 12/09/2015.

Conditional knockout of the androgen receptor in gonadotropes reveals crucial roles for androgen in gonadotropin synthesis and surge in female mice.

Wu S, Chen Y, Fajobi T, DiVall SA, Chang C, Yeh S, Wolfe A

Molecular endocrinology.. 2014 October 28 (10):1670-81. Epub 08/26/2014.

Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome.

Yu IC, Lin HY, Sparks JD, Yeh S, Chang C

Diabetes.. 2014 October 63 (10):3180-8. Epub 1900 01 01.

Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo.

Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S

Oncotarget.. 2014 September 155 (17):7917-35. Epub 1900 01 01.

ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2?/VEGF signaling pathway.

He D, Li L, Zhu G, Liang L, Guan Z, Chen Y, Yeh S, Chang C

Cancer research.. 2014 August 1574 (16):4420-30. Epub 06/12/2014.

Androgen receptor enhances kidney stone-CaOx crystal formation via modulation of oxalate biosynthesis & oxidative stress.

Liang L, Li L, Tian J, Lee SO, Dang Q, Huang CK, Yeh S, Erturk E, Bushinsky D, Chang LS, He D, Chang C

Molecular endocrinology.. 2014 August 28 (8):1291-303. Epub 06/23/2014.

Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver.

Chang C, Lee SO, Yeh S, Chang TM

Oncogene.. 2014 June 1933 (25):3225-34. Epub 07/22/2013.

Estrogen receptor ? in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3.

Slavin S, Yeh CR, Jun D, Yu S, Miyamoto H, Messing EM, Yeh S

Carcinogenesis.. 2014 June 35 (6):1301-9. Epub 12/28/2013.

Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Ma WL, Lai HC, Yeh S, Cai X, Chang C

Endocrine-related cancer.. 2014 June 21 (3):R165-82. Epub 05/06/2014.

Suppression of ER? signaling via ER? knockout or antagonist protects against bladder cancer development.

Hsu I, Chuang KL, Slavin S, da J, Lim WX, Pang ST, O'Brien JH, Yeh S

Carcinogenesis.. 2014 March 35 (3):651-61. Epub 10/22/2013.

The expression and evaluation of androgen receptor in human renal cell carcinoma.

Zhu G, Liang L, Li L, Dang Q, Song W, Yeh S, He D, Chang C

Urology.. 2014 February 83 (2):510.e19-24. Epub 12/12/2013.

The evolving understanding of microRNA in bladder cancer.

Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM

Urologic oncology.. 2014 January 32 (1):41.e31-40. Epub 08/02/2013.

Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.

Soh SF, Huang CK, Lee SO, Xu D, Yeh S, Li J, Yong EL, Gong Y, Chang C

Journal of pharmaceutical and biomedical analysis.. 2014 January 88 :117-22. Epub 08/27/2013.

Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation.

Shang Z; Niu Y; Cai Q; Chen J;, Tian J; Yeh S; Lai KP; Chang C.

Tumour Biol. 2014; .

The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth.

Xu D, Lin TH, Yeh CR, Cheng MA, Chen LM, Chang C, Yeh S

BioMed research international.. 2014 2014 :713263. Epub 08/13/2014.

Urethral dysfunction in female mice with estrogen receptor ? deficiency.

Chen YH, Chen CJ, Yeh S, Lin YN, Wu YC, Hsieh WT, Wu BT, Ma WL, Chen WC, Chang C, Chen HY

PloS one.. 2014 9 (9):e109058. Epub 10/02/2014.

Estrogen receptors in prostate development and cancer.

Yeh CR, Da J, Song W, Fazili A, Yeh S

American journal of clinical and experimental urology.. 2014 2 (2):161-8. Epub 07/12/2014.

Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

Lai KP, Huang CK, Fang LY, Izumi K, Lo CW, Wood R, Kindblom J, Yeh S, Chang C

Molecular endocrinology.. 2013 October 27 (10):1617-31. Epub 07/26/2013.

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.

Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C

Cell death & disease.. 2013 August 84 (8):e764. Epub 08/08/2013.

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C

The Journal of biological chemistry.. 2013 July 5288 (27):19359-69. Epub 05/16/2013.

Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells.

Chang C, Lee SO, Wang RS, Yeh S, Chang TM

Biology of reproduction.. 2013 July 89 (1):21. Epub 07/25/2013.

Endothelial cells enhance prostate cancer metastasis via IL-6?androgen receptor?TGF-??MMP-9 signals.

Wang X, Lee SO, Xia S, Jiang Q, Luo J, Li L, Yeh S, Chang C

Molecular cancer therapeutics.. 2013 June 12 (6):1026-37. Epub 03/27/2013.

Role of oestrogen receptors in bladder cancer development.

Hsu I, Vitkus S, Da J, Yeh S

Nature reviews. Urology.. 2013 June 10 (6):317-26. Epub 04/16/2013.

New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Yamashita S, Liang L, Tian J, Li L, Jiang Q, Huang CK, Niu Y, Yeh S, Chang C

Journal of molecular cell biology.. 2013 February 5 (1):14-26. Epub 07/24/2012.

Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-?B-mediated PTP1B expression.

Yu IC, Lin HY, Liu NC, Sparks JD, Yeh S, Fang LY, Chen L, Chang C

Diabetes.. 2013 February 62 (2):411-23. Epub 11/08/2012.

New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.

Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S, Chang C

The American journal of pathology.. 2013 February 182 (2):460-73. Epub 12/04/2012.

Distinct function of estrogen receptor ? in smooth muscle and fibroblast cells in prostate development.

Vitkus S, Yeh CR, Lin HH, Hsu I, Yu J, Chen M, Yeh S

Molecular endocrinology.. 2013 January 27 (1):38-49. Epub 11/30/2012.

Targeting thymic epithelia AR enhances T-cell reconstitution and bone marrow transplant grafting efficacy.

Lai KP, Lai JJ, Chang P, Altuwaijri S, Hsu JW, Chuang KH, Shyr CR, Yeh S, Chang C

Molecular endocrinology.. 2013 January 27 (1):25-37. Epub 12/18/2012.

The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells

Shyr CR; Chen CC; Hsieh TF; Chang CH; Ma WL; Yeh S; Messing E; Li TH; Li FY; Chang C.

Endocrine. 2013; .

Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage

Li L; Xie H; Liang ; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C.

Carcinogenesis. 2013; .

Androgen receptor in human prostate cancer-associated fibroblasts promotes prostate cancer epithelial cell growth and invasion.

Yu S; Xia ; Yang D; Wang K;Yeh S; Gao Z; Chang C.

Medical Oncology. 2013; .

Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.

Soh SF;Huang C; Lee SO; Xu D; Yeh S; Li J; Yong EL; Gong Y; Chang C.

J Pharm Biomed Anal. 2013; .

Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells.

Chang C; Lee SO; Wang RS; Yeh S; Chang TM.

Biology of Reproduction. 2013; .

Androgen receptor (AR) pathophysiological roles in androgen-related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cells.

Chang C, Yeh S, Lee SO, Chang TM

Nuclear receptor signaling. 2013 11 :e001. Epub 08/19/2013.

Targeting androgen receptor leads to suppression of prostate cancer via induction of autophagy.

Jiang Q, Yeh S, Wang X, Xu D, Zhang Q, Wen X, Xia S, Chang C

The Journal of urology.. 2012 October 188 (4):1361-8. Epub 08/17/2012.

Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines.

Lai KP, Yamashita S, Huang CK, Yeh S, Chang C

EMBO molecular medicine.. 2012 August 4 (8):791-807. Epub 06/29/2012.

Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.

Ma WL, Hsu CL, Yeh CC, Wu MH, Huang CK, Jeng LB, Hung YC, Lin TY, Yeh S, Chang C

Hepatology : official journal of the American Association for the Study of Liver Diseases.. 2012 July 56 (1):176-85. Epub 06/05/2012.

Reduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor ? knockout mice.

Chen M, Yeh CR, Shyr CR, Lin HH, Da J, Yeh S

Asian journal of andrology.. 2012 July 14 (4):546-55. Epub 05/21/2012.

Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.

Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S

BJU international.. 2012 June 109 (11):1716-26. Epub 01/05/2012.

The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells.

Xu D, Lin TH, Zhang C, Tsai YC, Li S, Zhang J, Yin M, Yeh S, Chang C

The Prostate.. 2012 May 1572 (7):803-16. Epub 09/19/2011.

Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells.

Lee SO, Tian J, Huang CK, Ma Z, Lai KP, Hsiao H, Jiang M, Yeh S, Chang C

The Journal of endocrinology.. 2012 May 213 (2):173-82. Epub 03/05/2012.

Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts.

Yu S, Yeh CR, Niu Y, Chang HC, Tsai YC, Moses HL, Shyr CR, Chang C, Yeh S

The Prostate.. 2012 March 72 (4):437-49. Epub 07/07/2011.

Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.

Xu D, Lin TH, Li S, Da J, Wen XQ, Ding J, Chang C, Yeh S

Cancer letters.. 2012 March 316 (1):11-22. Epub 10/10/2011.

Loss of epithelial oestrogen receptor ? inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models.

Chen M, Yeh CR, Chang HC, Vitkus S, Wen XQ, Bhowmick NA, Wolfe A, Yeh S

The Journal of pathology.. 2012 January 226 (1):17-27. Epub 11/09/2011.

Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor.

Lai KP, Yamashita S, Vitkus S, Shyr CR, Yeh S, Chang C

Molecular endocrinology.. 2012 January 26 (1):52-66. Epub 12/01/2011.

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C

Neoplasia : an international journal for oncology research.. 2012 January 14 (1):74-83. Epub 1900 01 01.

Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor.

Lai KP;, Yamashita S; Vitkus S; Shyr CR; Yeh S; Chang C.

Mol Endocrinol. 2012; .

Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells.

Lee SO1, Tian J, Huang CK, Ma Z, Lai KP, Hsiao H, Jiang M, Yeh S, Chang C.

Journal of Endocrinology. 2012; .

N-3 poly-unsaturated fatty acids shift estrogen signaling to inhibit human breast cancer cell growth.

Cao W, Ma Z, Rasenick MM, Yeh S, Yu J

PloS one.. 2012 7 (12):e52838. Epub 12/28/2012.

Altered prostate epithelial development and IGF-1 signal in mice lacking the androgen receptor in stromal smooth muscle cells.

Yu S, Zhang C, Lin CC, Niu Y, Lai KP, Chang HC, Yeh SD, Chang C, Yeh S

The Prostate.. 2011 April 71 (5):517-24. Epub 10/13/2010.

Increased CK5/CK8-positive intermediate cells with stromal smooth muscle cell atrophy in the mice lacking prostate epithelial androgen receptor.

Niu Y; Wang J; Shang Z; Huang SP; Shyr CR; Yeh S; Chang C.

PLoS One. 2011; .

Tissue-specific knockout of androgen receptor in mice.

Lin TH, Yeh S, Chang C

Methods in molecular biology.. 2011 776 :275-93. Epub 1900 01 01.

Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.

Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C

Oncogene.. 2010 June 2429 (25):3593-604. Epub 05/03/2010.

Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth.

Shyr CR, Tsai MY, Yeh S, Kang HY, Chang YC, Wong PL, Huang CC, Huang KE, Chang C

The Prostate.. 2010 February 170 (2):190-9. Epub 1900 01 01.

Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription.

Wu MH; Ma WL; Hsu CL; Chen YL; Ou JH; Ryan CK; Hung YC; Yeh S; Chang C.

Sci Transl Med. 2010; .

Reduced Expression of Tocopherol-Associated Protein (TAP/Sec14L2) in Human Breast Cancer.

Wang X, Ni J, Hsu CL, Johnykutty S, Tang P, Ho YS, Lee CH, Yeh S

Cancer investigation.. 2009 June 22 :1. Epub 6/22/2009.

Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas.

Johnykutty S, Tang P, Zhao H, Hicks DG, Yeh S, Wang X

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2009 June 22 (6):770-5. Epub 03/20/2009.

Genomic responses from the estrogen-responsive element-dependent signaling pathway mediated by estrogen receptor alpha are required to elicit cellular alterations.

Nott SL, Huang Y, Li X, Fluharty BR, Qiu X, Welshons WV, Yeh S, Muyan M

The Journal of biological chemistry.. 2009 May 29284 (22):15277-88. Epub 03/24/2009.

CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.

Chen M, Ni J, Chang HC, Lin CY, Muyan M, Yeh S

Carcinogenesis.. 2009 May 30 (5):841-50. Epub 01/06/2009.

Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells.

Altuwaijri S, Chuang KH, Lai KP, Lai JJ, Lin HY, Young FM, Bottaro A, Tsai MY, Zeng WP, Chang HC, Yeh S, Chang C

Molecular endocrinology.. 2009 April 23 (4):444-53. Epub 01/22/2009.

Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice.

Wang RS, Yeh S, Tzeng CR, Chang C

Endocrine reviews.. 2009 April 30 (2):119-32. Epub 01/27/2009.

In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.

Ni J, Mai T, Pang ST, Haque I, Huang K, DiMaggio MA, Xie S, James NS, Kasi D, Chemler SR, Yeh S

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2009 February 115 (3):898-906. Epub 1900 01 01.

RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.

Yin Y, Ni J, Chen M, Guo Y, Yeh S

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2009 January 115 (1):190-200. Epub 1900 01 01.

Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice.

Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S, Chang C, Messing EM, Yeh S

Endocrinology.. 2009 January 150 (1):251-9. Epub 08/28/2008.

Generation and characterization of a complete null estrogen receptor alpha mouse using Cre/LoxP technology.

Chen M, Wolfe A, Wang X, Chang C, Yeh S, Radovick S

Molecular and cellular biochemistry.. 2009 January 321 (1-2):145-53. Epub 10/25/2008.

The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer

Yu SQ; Lai KP; Xia SJ; Chang HC; Chang C; Yeh S.

Asian J Androl. 2009; .

ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells.

Chen M, Ni J, Zhang Y, Muyan M, Yeh S

The Prostate.. 2008 September 168 (12):1273-82. Epub 1900 01 01.

Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation.

Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC, Chang C

Cancer research.. 2008 September 168 (17):7110-9. Epub 1900 01 01.

Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.

Ma WL, Ma CL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S, Chang C

Gastroenterology.. 2008 September 135 (3):947-55, 955.e1-5. Epub 05/22/2008.

Targeting the stromal androgen receptor in primary prostate tumors at earlier stages.

Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, Huang SP, Lardy H, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2008 August 26105 (34):12188-93. Epub 08/22/2008.

Androgen receptor is a tumor suppressor and proliferator in prostate cancer.

Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2008 August 26105 (34):12182-7. Epub 08/22/2008.

Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor.

Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD, Yeh S, Chang C

Hepatology : official journal of the American Association for the Study of Liver Diseases.. 2008 June 47 (6):1924-35. Epub 1900 01 01.

Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue.

Yu IC, Lin HY, Liu NC, Wang RS, Sparks JD, Yeh S, Chang C

Endocrinology.. 2008 May 149 (5):2361-8. Epub 02/14/2008.

Infertility with defective spermatogenesis and steroidogenesis in male mice lacking androgen receptor in Leydig cells.

Xu Q, Lin HY, Yeh SD, Yu IC, Wang RS, Chen YT, Zhang C, Altuwaijri S, Chen LM, Chuang KH, Chiang HS, Yeh S, Chang C

Endocrine.. 2007 August 32 (1):96-106. Epub 10/23/2007.

Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor.

Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, Niu Y, Tsai MY, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2007 July 31104 (31):12679-84. Epub 07/25/2007.

Promotion of bladder cancer development and progression by androgen receptor signals.

Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C

Journal of the National Cancer Institute.. 2007 April 499 (7):558-68. Epub 1900 01 01.

Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells.

Ni J, Pang ST, Yeh S

The Prostate.. 2007 April 167 (5):463-71. Epub 1900 01 01.

The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.

Yin Y, Ni J, Chen M, DiMaggio MA, Guo Y, Yeh S

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2007 April 113 (7):2271-80. Epub 1900 01 01.

Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54.

Yang Z, Chang YJ, Miyamoto H, Yeh S, Yao JL, di Sant'Agnese PA, Tsai MY, Chang C

Endocrinology.. 2007 March 148 (3):1340-9. Epub 11/16/2006.

ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.

Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, Merry DE, Sobue G, Chen LM, Chang SS, Chang C

Nature medicine.. 2007 March 13 (3):348-53. Epub 03/04/2007.

Alpha-vitamin E derivative, RRR-alpha-tocopheryloxybutyric acid inhibits the proliferation of prostate cancer cells.

Chang E, Ni J, Yin Y, Lin CC, Chang P, James NS, Chemler SR, Yeh S

Asian journal of andrology.. 2007 January 9 (1):31-9. Epub 1900 01 01.

The roles of alpha-vitamin E and its analogues in prostate cancer.

Ni J, Yeh S

Vitamins and hormones.. 2007 76 :493-518. Epub 1900 01 01.

Differential effects of spermatogenesis and fertility in mice lacking androgen receptor in individual testis cells.

Tsai MY, Yeh SD, Wang RS, Yeh S, Zhang C, Lin HY, Tzeng CR, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2006 December 12103 (50):18975-80. Epub 12/01/2006.

Androgen receptor in sertoli cell is essential for germ cell nursery and junctional complex formation in mouse testes.

Wang RS, Yeh S, Chen LM, Lin HY, Zhang C, Ni J, Wu CC, di Sant'Agnese PA, deMesy-Bentley KL, Tzeng CR, Chang C

Endocrinology.. 2006 December 147 (12):5624-33. Epub 09/14/2006.

Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells.

Zhang C, Yeh S, Chen YT, Wu CC, Chuang KH, Lin HY, Wang RS, Chang YJ, Mendis-Handagama C, Hu L, Lardy H, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2006 November 21103 (47):17718-23. Epub 11/09/2006.

Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.

Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, Xie S, Chen M, Simons B, Chang P, di Sant'Agnese A, Messing EM, Yeh S

Cancer research.. 2005 November 165 (21):9807-16. Epub 1900 01 01.

Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor.

Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C

Diabetes.. 2005 June 54 (6):1717-25. Epub 1900 01 01.

Cell culture block array for immunocytochemical study of protein expression in cultured cells.

Li R, Ni J, Bourne PA, Yeh S, Yao J, di Sant'Agnese PA, Huang J

Applied immunohistochemistry & molecular morphology : AIMM. 2005 March 13 (1):85-90. Epub 1900 01 01.

Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth.

Hsu CL, Chen YL, Ting HJ, Lin WJ, Yang Z, Zhang Y, Wang L, Wu CT, Chang HC, Yeh S, Pimplikar SW, Chang C

Molecular endocrinology.. 2005 February 19 (2):350-61. Epub 10/28/2004.

Expression of androgen receptor associated protein 55 (ARA55) in the developing human fetal prostate.

Cai G; Huang H; Shapiro ; Zhou H; Yeh S; Melamed J; Greco MA; Lee P.

Journal of Urology. 2005; .

Androgen receptor regulates expression of skeletal muscle-specific proteins and muscle cell types.

Altuwaijri S, Lee DK, Chuang KH, Ting HJ, Yang Z, Xu Q, Tsai MY, Yeh S, Hanchett LA, Chang HC, Chang C

Endocrine.. 2004 October 25 (1):27-32. Epub 1900 01 01.

Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.

Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, Hsu CL, Ting HJ, Lin HK, Wang L, Kim E, Ni J, Chang C

The Journal of biological chemistry.. 2004 August 6279 (32):33438-46. Epub 05/27/2004.

Subfertility and defective folliculogenesis in female mice lacking androgen receptor.

Hu YC, Wang PH, Yeh S, Wang RS, Xie C, Xu Q, Zhou X, Chao HT, Tsai MY, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2004 August 3101 (31):11209-14. Epub 07/26/2004.

Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells.

Chang C, Chen YT, Yeh SD, Xu Q, Wang RS, Guillou F, Lardy H, Yeh S

Proceedings of the National Academy of Sciences of the United States of America.. 2004 May 4101 (18):6876-81. Epub 04/23/2004.

RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness.

Zhang M, Altuwaijri S, Yeh S

Oncogene.. 2004 April 1523 (17):3080-8. Epub 1900 01 01.

Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells.

Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Keng P, Chang C

Molecular and cellular biology.. 2004 March 24 (5):2202-13. Epub 1900 01 01.

ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation.

Zhang Y, Yang Y, Yeh S, Chang C

Molecular and cellular biology.. 2004 February 24 (3):1044-57. Epub 1900 01 01.

Cellular and molecular effects of alpha-tocopheryloxybutyrate: lessons for the design of vitamin E analog for cancer prevention

Wu Y; Zu K; Ni J; Yeh S; Kasi D; James NS; Chemler S; Ip C.

Anticancer Research. 2004; .

Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor.

Yeh S, Hu YC, Wang PH, Xie C, Xu Q, Tsai MY, Dong Z, Wang RS, Lee TH, Chang C

The Journal of experimental medicine.. 2003 December 15198 (12):1899-908. Epub 1900 01 01.

Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.

Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L, Chang C

Cancer research.. 2003 November 163 (21):7106-12. Epub 1900 01 01.

Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator.

Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, Chang HC, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C

Cancer research.. 2003 August 1563 (16):4888-94. Epub 1900 01 01.

The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs.

Hsu CL, Chen YL, Yeh S, Ting HJ, Hu YC, Lin H, Wang X, Chang C

The Journal of biological chemistry.. 2003 June 27278 (26):23691-8. Epub 04/24/2003.

Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells.

Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S, Chang C

The Journal of biological chemistry.. 2003 May 30278 (22):19619-26. Epub 03/20/2003.

Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery.

Ni J, Chen M, Zhang Y, Li R, Huang J, Yeh S

Biochemical and biophysical research communications.. 2003 January 10300 (2):357-63. Epub 1900 01 01.

The androgen receptor in spermatogenesis.

Collins LL, Lee HJ, Chen YT, Chang M, Hsu HY, Yeh S, Chang C

Cytogenetic and genome research.. 2003 103 (3-4):299-301. Epub 1900 01 01.

Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues.

Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, Huang KE, Lin H, Yeh SD, Altuwaijri S, Zhou X, Xing L, Boyce BF, Hung MC, Zhang S, Gan L, Chang C, Hung MC

Proceedings of the National Academy of Sciences of the United States of America.. 2002 October 1599 (21):13498-503. Epub 10/07/2002.

Mutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of 17beta-estradiol-induced androgen receptor transactivation.

Thin TH, Kim E, Yeh S, Sampson ER, Chen YT, Collins LL, Basavappa R, Chang C

The Journal of biological chemistry.. 2002 September 27277 (39):36499-508. Epub 06/14/2002.

Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells.

Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S

Proceedings of the National Academy of Sciences of the United States of America.. 2002 May 2899 (11):7408-13. Epub 1900 01 01.

Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator.

Wang X, Yang Y, Guo X, Sampson ER, Hsu CL, Tsai MY, Yeh S, Wu G, Guo Y, Chang C

The Journal of biological chemistry.. 2002 May 3277 (18):15426-31. Epub 02/20/2002.

A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth.

Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C

The Journal of biological chemistry.. 2002 February 15277 (7):4609-17. Epub 10/22/2001.

Supervillin associates with androgen receptor and modulates its transcriptional activity.

Ting HJ, Yeh S, Nishimura K, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2002 January 2299 (2):661-6. Epub 01/15/2002.

Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells.

Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y, Chang C

The Journal of biological chemistry.. 2001 November 2276 (44):40417-23. Epub 08/16/2001.

Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.

Lin HK, Yeh S, Kang HY, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2001 June 1998 (13):7200-5. Epub 06/12/2001.

From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells.

Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2001 March 1398 (6):3018-23. Epub 03/06/2001.

Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.

Sampson ER, Yeh SY, Chang HC, Tsai MY, Wang X, Ting HJ, Chang C

Journal of biological regulators and homeostatic agents.. 2001 15 (2):123-9. Epub 1900 01 01.

Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.

Yeh S, Sampson ER, Lee DK, Kim E, Hsu CL, Chen YL, Chang HC, Altuwaijri S, Huang KE, Chang C

Journal of the Formosan Medical Association = Taiwan yi zhi.. 2000 December 99 (12):885-94. Epub 1900 01 01.

Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.

Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 2000 October 1097 (21):11256-61. Epub 1900 01 01.

Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.

Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, Ting HJ, Rahman M, Lin HK, Fujimoto N, Hu YC, Mizokami A, Huang KE, Chang C

Endocrine.. 1999 October 11 (2):195-202. Epub 1900 01 01.

Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.

Chang HC, Miyamoto H, Marwah P, Lardy H, Yeh S, Huang KE, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1999 September 2896 (20):11173-7. Epub 1900 01 01.

Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma.

Heinlein CA, Ting HJ, Yeh S, Chang C

The Journal of biological chemistry.. 1999 June 4274 (23):16147-52. Epub 1900 01 01.

Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators.

Yeh S, Chang HC, Miyamoto H, Takatera H, Rahman M, Kang HY, Thin TH, Lin HK, Chang C

The Keio journal of medicine.. 1999 June 48 (2):87-92. Epub 1900 01 01.

Isolation of Ku70-binding proteins (KUBs).

Yang CR, Yeh S, Leskov K, Odegaard E, Hsu HL, Chang C, Kinsella TJ, Chen DJ, Boothman DA

Nucleic acids research.. 1999 May 1527 (10):2165-74. Epub 1900 01 01.

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1999 May 1196 (10):5458-63. Epub 1900 01 01.

Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor.

Kang HY, Yeh S, Fujimoto N, Chang C

The Journal of biological chemistry.. 1999 March 26274 (13):8570-6. Epub 1900 01 01.

Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate.

Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C

The Journal of biological chemistry.. 1999 March 19274 (12):8316-21. Epub 1900 01 01.

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C.

Proc Natl Acad Sci U S A. 1999; .

Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma

Heinlein CA; Ting HJ; Yeh S; Chang C.

J Biol Chem. 1999; .

Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.

Miyamoto H, Yeh S, Lardy H, Messing E, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1998 September 1595 (19):11083-8. Epub 1900 01 01.

Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells.

Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C

Biochemical and biophysical research communications.. 1998 July 20248 (2):361-7. Epub 1900 01 01.

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.

Miyamoto H, Yeh S, Wilding G, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1998 June 2395 (13):7379-84. Epub 1900 01 01.

From estrogen to androgen receptor: a new pathway for sex hormones in prostate.

Yeh S, Miyamoto H, Shima H, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1998 May 1295 (10):5527-32. Epub 1900 01 01.

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.

Miyamoto H; Yeh S; Wilding G; Chang C.

Proc Natl Acad Sci U S A. 1998; .

Hydroxyflutamide may not always be a pure antiandrogen.

Yeh S, Miyamoto H, Chang C

Lancet.. 1997 March 22349 (9055):852-3. Epub 1900 01 01.

Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.

Yeh S, Chang C

Proceedings of the National Academy of Sciences of the United States of America.. 1996 May 2893 (11):5517-21. Epub 1900 01 01.

Gene expression of the androgen repressed rat TR2 orphan receptor: a member of steroid receptor superfamily.

Ideta R; Yeh S; Lee Y; Adachi K; Takeda H; Su C; Saltzman A; Chang C.

Endocrine. 1995; .

Androgen receptor: an overview.

Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A

Critical reviews in eukaryotic gene expression.. 1995 5 (2):97-125. Epub 1900 01 01.

Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily.

Chang C, Da Silva SL, Ideta R, Lee Y, Yeh S, Burbach JP

Proceedings of the National Academy of Sciences of the United States of America.. 1994 June 2191 (13):6040-4. Epub 1900 01 01.

Identification of 3',5'-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter.

Mizokami A, Yeh SY, Chang C

Molecular endocrinology.. 1994 January 8 (1):77-88. Epub 1900 01 01.

Books

Breast and Prostate Cancers (2012)

Chapter: Differential Functions of Stromal and Epithelial Androgen Receptor in Prostate Cancer Before and After Castration Resistant Stage. Advances in Rapid Sex-Steroid Action, New Challenges and New Chances

Authors: Lee SO, Lai KP, Yeh S, Chang C.

Publisher: Springer 2012

Female Sex Hormones and Cancers (2010)

Chapter: Estrogens and Estrogen Receptors in Prostate Development, Estrogenization, and Carcinogenesis

Authors: Chen M and Yeh S*

Publisher: Nova Science Publishers Inc 2010

Androgen Action in Prostate Cancer (2009)

Chapter: Differential Roles of Androgen Receptor in Prostate Development and Cancer Progression

Authors: Yeh S, Niu Y, Miyamoto H, Chang T, Chang C.

Publisher: World Scientific Publishing 2009

Prostate Cancer: Basic Mechanisms and Therapeutic Approaches (2005)

Chapter: Functions of Estrogen Receptor in Prosate and Prostate Cancer

Authors: Yeh, S*, Chen, M., Ni, J., Yin, Y., Chang, C., Zhang, M., and Wen, X.

Publisher: World Scientific Publishing 2005

Prostate Cancer: Basic Mechanisms and Therapeutic Approaches (2005)

Chapter: Roles of Vitamin E in Prostate and Prostate Cancer

Authors: Yeh S*, Ni J, Chang E, Yin Y, and Chen M.

Publisher: World Scientific Publishing 2005

Prostate Cancer: Basic Mechanisms and Therapeutic Approaches (2005)

Chapter: Study of androgen receptor roles in prostate cancer using mice lacking functional prostate androgen receptor

Authors: Wu C, Yeh S, Xu Q, Yang Z, Chang P, Yu Y, and Chang C.

Publisher: World Scientific Publishing 2005

Androgens and Androgen Receptor Mechanisms, Functions, and Clinical Applications (2002)

Chapter: Nature Products and Environmental Androgens and Antiandrogens.

Authors: Wang MS, Yeh S, Su CY, Yang CY.

Publisher: Kluwer Academic Publishers 2002

Yeast Hybrid Technologies (2000)

Chapter: Yeast two-hybrid screening of associated proteins and characterization of mutant androgen receptors

Authors: Nishimura K, Sampson E, Yan S, Kim E, Wang X, Uemura H, Wang C, Fujimoto N, Kang H, Yeh S, and Chang C

Publisher: Eaton Publishing 2000

Molecular Basis of Steroid Hormone Function - New Targets for Intervention (1997)

Chapter: Androgen receptor coregulators

Authors: Yeh S, Miyamoto H, Huang S, Kinoshita H, Fujimoto N, Nishimura K, Inui S, Mizokami A, Uemura H, Chang C.

Publisher: Springer 1997